What Mounjaro does to your body — and why it works differently from older treatments

How does Mounjaro change the body's hunger signals?

The short answer is that tirzepatide resets the conversation between your gut and your brain. Two hormones released after eating (GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)) normally tell the brain that food has arrived and that appetite should fall. In people carrying excess weight, that signalling is often blunted. Tirzepatide binds to both receptors at once, amplifying both signals at the same time. No medicine approved in the UK before it worked on both pathways together, which explains why clinical researchers described it as a meaningful step forward rather than an incremental one.

Practically, this translates into feeling full sooner during a meal and staying full longer between meals. Food cravings (particularly for high-fat, high-calorie foods) tend to reduce over the first weeks of treatment. This is not willpower; it is pharmacology altering the hormonal environment that drives eating behaviour. The NHS medicines page for tirzepatide describes this mechanism at a patient-friendly level if you want a plain-language companion to the clinical detail here.

Gastric emptying also slows, meaning food moves through the stomach more gradually. That contributes to the feeling of fullness but is also the reason nausea is the most commonly reported early side effect, your stomach is adjusting to a new transit speed. For most people this settles, particularly when the dose titration schedule is followed properly. You can read more about the effects of tirzepatide on appetite, digestion and the body's signalling pathways on our tirzepatide overview page.

What happens to weight and metabolism over time on Mounjaro?

Weight loss on tirzepatide is not evenly distributed across the treatment period. Most people notice the greatest rate of change in the first few months, as the dose is gradually increased by the prescriber and the body adjusts. The SURMOUNT-1 trial (which enrolled 2,539 adults with obesity and followed them for 72 weeks) recorded average body-weight reductions of around 20–21% at the 15 mg dose; in some analyses the figure reached approximately 22.5%. These are trial averages, not guarantees for any individual, but they place tirzepatide among the most effective medicines ever studied for weight management.

Beyond the scales, the body's metabolic picture often shifts alongside weight. Blood pressure, fasting glucose, triglycerides and cholesterol levels improved in trial participants, and the cardiovascular risk profile for many improved as a result. These are secondary effects of weight loss itself as much as direct drug effects, the two are hard to disentangle. What the NICE appraisal of tirzepatide (TA1026) concluded is that the overall benefit profile was sufficient to recommend it for adults with a BMI of 35 or above plus at least one weight-related condition, alongside lifestyle support. Ethnic-background thresholds are lower under that guidance, worth reviewing if that applies to you.

Muscle mass is worth flagging. Rapid weight loss from any cause can reduce lean tissue as well as fat, which is why prescribers and clinical guidance consistently emphasise adequate protein intake and resistance activity during treatment. The medicine does the appetite work; nutrition and movement protect the composition of what remains. Our page on the wider effects of Mounjaro covers the metabolic picture in more depth.

What are the main side effects people actually experience?

Gastrointestinal symptoms are the most common: nausea, loose stools, constipation, reflux, burping and occasional vomiting. They are not random, they follow a predictable pattern tied to the dose and to how quickly gastric emptying has slowed. Most are at their worst in the first week or two after starting or after a dose increase, then ease. Eating smaller portions, avoiding rich or fatty foods and staying well hydrated all help during the adjustment period.

Injection-site reactions (redness, mild swelling, brief discomfort) are also reported. Rotating between the abdomen, thigh and upper arm at each weekly injection reduces this. Fatigue and mild headache appear in some people during the early weeks.

Rarer but more serious signals require urgent medical attention. Severe, persistent stomach pain that radiates to the back (with or without vomiting) should prompt an immediate call for help, as this pattern is associated with acute pancreatitis. In January 2026 the MHRA issued a formal Drug Safety Update on GLP-1 medicines highlighting pancreatitis as an infrequent but potentially serious risk. Symptoms of gallbladder problems, signs of dehydration from prolonged GI illness, and any signs of an allergic reaction also need prompt assessment. A more detailed breakdown sits on our page on Mounjaro's adverse effects, and suspected reactions can be reported directly through the MHRA Yellow Card scheme. Some effects ease after the first injection; others are worth discussing with your prescriber before changing anything yourself. Our guide to what to expect after each dose covers the first-few-days picture specifically.

Are there effects on the body that aren't about weight?

Yes. Several deserve an honest mention. Mounjaro affects how the body processes blood sugar, even in people who do not have type 2 diabetes, which is part of why it is licensed for both conditions. For people on diabetes medicines that can cause low blood sugar, concurrent use needs careful prescriber management.

There are also effects that some people find unexpected. Menstrual cycle changes have been reported, possibly connected to the hormonal and weight changes that accompany treatment, what is known and what remains uncertain about Mounjaro's effects on periods is covered in a dedicated page. Hair thinning (telogen effluvium) can follow significant or rapid weight loss from any cause and is usually temporary, though it can be distressing.

For people considering surgery or who take oral contraceptives, there are specific interaction points. Tirzepatide slows gastric emptying, which may affect how oral medications are absorbed. Women taking the combined pill are advised to use an additional non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase. The anaesthetic team needs to know about tirzepatide use before any procedure. These are not reasons to avoid treatment, they are reasons to have an honest, detailed conversation with a prescriber beforehand.

Tirzepatide is a prescription-only medicine, so access in the UK (whether through the NHS or privately) begins with a clinical assessment. If you are considering whether it might be right for you, our free consultation is reviewed the same day by a GPhC-registered prescriber, not an automated system. If you order before 12pm on a working day, treatment that has been clinically approved is dispatched the same afternoon and arrives with DPD tracking the next working day, in a plain, unbranded box, the pen inside looking exactly like anything else in your medication drawer.